サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1643895

注射剤デリバリーの世界市場（2025年～2033年）

Global Injectable Drug Delivery Market - 2025-2033

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.35円
注射剤デリバリーの世界市場（2025年～2033年）
出版日: 2025年01月27日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の注射剤デリバリーの市場規模は、2024年に7億4,430万米ドルに達し、2033年には 12億5,840万米ドルに達すると予測され、予測期間2025年～2033年のCAGRは5.8%で成長する見通しです。

注射剤デリバリーシステムは、注射によって投与される方法であり、制御された徐放性を有するハイドロゲル製剤の観点から適合させることができます。システムは、多くのin situゲルシステムを使用することにより、長期放出を提供することを意図しています。このアプローチにより、体内への薬剤の導入が延長されるため、ドラッグデリバリーの効率が飛躍的に向上し、治療成績が向上し、患者の治療へのアドヒアランスが高まります。

市場力学：

促進要因と抑制要因

慢性疾患の有病率の上昇

がんや糖尿病などの慢性疾患の罹患率が上昇しているため、薬剤を送達するための浸透技術が必要とされています。侵襲的技術が広く受け入れられるかどうかが、世界の注射剤デリバリー市場の成長率を大きく左右します。訓練を受けた医療専門家が利用できることが、その利点を促進しています。

例えば、2024年1月、ノースカロライナ州のチャペルヒルにあるこの質素な大学の科学者たちは、時空間オンデマンドパッチ（SOP）として知られるユニークなドラッグデリバリー方法を開発しました。その薄くて柔らかいパッチプラットフォームは、バンドエイドのようなデザインで、装着性を促進し、慢性疾患患者にとって重要な要素である快適性と利便性を実現します。

さらに、米国における自己免疫疾患の有病率は、既存の文献と、スカンジナビア諸国のような充実した疫学データを持つ地域からの補足的な一次データの収集に基づいて推定されています。推定された全自己免疫疾患の合計有病率は、米国人口の約3%が影響を受けていることを示しており、これは数百万人、推定約1,000万人が罹患している可能性があることを示唆しています。

複雑な製造

世界の注射剤デリバリー市場は、複雑な製造、患者のコンプライアンスへの懸念、経口、経皮、吸入システムなどの代替方法との競合、低・中所得国におけるコールドチェーン保管や流通のための限られたインフラなど、いくつかの課題に直面しています。これらの要因は、アクセシビリティを制限し、注射剤治療の普及を妨げるため、市場の成長可能性を制限する可能性があります。注射剤の製造の複雑さ、注射針とそれに伴う痛みに対する恐怖心、低・中所得国におけるコールドチェーン保管と流通のためのインフラの制限などが、市場の成長の可能性をさらに制限しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 慢性疾患の罹患率の上昇
    • 抑制要因
      • 複雑な製造
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 デバイスタイプ別

  • オートインジェクター
  • 従来型注射器
  • ペン型注射器
  • ウェアラブルインジェクター
  • その他

第7章 用途別

  • 腫瘍学
    • 自己免疫疾患
    • ホルモン障害
    • 希少疾患
    • その他

第8章 使用パターン別

  • 治療ケア
  • 免疫
  • その他の使用パターン

第9章 流通チャネル別

  • 院内薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • Becton Dickinson & Company
    • 会社概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 実績および予測の製品販売
      • 製品販売量
    • 財務概要
      • 企業収益
      • 地域別収益分配
      • 収益予測
    • 主な発展
      • 合併と買収
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Baxter International, Inc
  • Gerresheimer AG
  • Pfizer Inc
  • Schott AG
  • Terumo Corporation
  • SHL Medical
  • Owen Mumford
  • Ypsomed
  • Union Medico
  • Similar data will be provided for each market player.
  • ApiJect Systems
    • パイプライン製品の説明
    • 製品の主要業績評価指標（KPI）
    • 主な活動
    • 市場参入のタイムライン
    • 製品普及率
    • 売上推定と予測
  • Alteogen Inc
  • Halozyme Therapeutics
  • Carmot Therapeutics

第12章 付録

目次
Product Code: MD799

The global injectable drug delivery market reached US$ 744.3 million in 2024 and is expected to reach US$ 1258.4 million by 2033, growing at a CAGR of 5.8% during the forecast period 2025-2033.

Injectable drug delivery systems are method which are administred through injection, which can be adapted in terms of hydrogel formulations that controlled and sustained release. The systems are intended to provide prolonged release by using many in situ gel systems. This approach tremendously augments the efficacious delivery of drugs as the introduction of medications in the body will be prolonged, which will improve the results of therapeutics and enhance patients' adherence to treatment.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Chronic Diseases

The upsurging of chronic diseases incidence such as cancer and diabetes have warranted penetrating technologies to deliver drugs. Where the mass acceptance of invasive techniques will greatly determine the rate of growth of the global injectable drug delivery market. Availability of trained medical experts has promoted their advantages.

For instance, in January 2024, Scientists from this humble University at Chapel Hill in North Carolina formulated a unique method of drug delivery known as the Spatiotemporal On-Demand Patch (SOP) that allows drug release from individual microneedles to be scheduled and triggered via a smartphone or computer command system. Its thin and soft patch platform is designed much like a Band-Aid in order to promote wearability, hence, comfort and convenience for users because this is a key factor involving chronically ill patients.

Male and Female Luer ComponentsMoreover, the prevalence of autoimmunities in the US has been estimated on the basis of publications and a supplementary collection of primary data from smaller, well-endowed epidemiological resources states like Scandinavian countries. Estimated combined prevalence of all autoimmune conditions is such that about 3% of the US population is affected-evidence to suggest that some millions, presumes about 10 million people are afflicted.

Complex Manufacturing

The global injectable drug delivery market faces several challenges, including complex manufacturing, patient compliance concerns, competition from alternative methods like oral, transdermal, and inhalation systems, and limited infrastructure for cold chain storage and distribution in low- and middle-income countries. These factors can limit the market's growth potential, as they restrict accessibility and hinder the widespread adoption of injectable treatments. The complexity of manufacturing injectable formulations, the fear of needles and associated pain, and the limited infrastructure for cold chain storage and distribution in low- and middle-income countries further limit the market's potential for growth.

For more details on this report - Request for Sample

Segment Analysis

The global injectable drug delivery market is segmented based on device type, application, usage pattern distribution channel and region.

Device Type:

Autoinjectors from the device segment is expected to dominate the Injectable Drug Delivery market share

The autoinjectors segment holds a major portion of the injectable drug delivery market share and is expected to continue to hold a significant portion of the injectable drug delivery market share during the forecast period.

Autoinjectors segment is expected to grow during the forecast period owing to the factors like siginificant product launches, advancements, moreover, autoinjectors are intuitive and user-friendly designed, requiring only a single button press to administer medication, minimizing errors and ensuring accurate dosing. However, they are not designed for multiple uses, raising sustainability concerns. Despite this, their user-friendly use continues to drive their popularity, with Nemera's PenDURA and PenVARIO platforms facilitating multi-dose pen injector ranges.

For instance, in June 2024, Instron announced the next-generation Autoinjector Testing System for complete functionality testing of pen and autoinjectors to ISO 11608. Developed in close cooperation with pharmaceutical companies and CDMOs, this system allows for measurement of a mixture of essential performances: cap removal, dose accuracy, activation force, injection time, needle depth, and needle guard lockout.

Moreover, in January 2024, Taisho Pharmaceutical Co., Ltd. has announced the launch of Nanozora 30mg Autoinjector for S.C. Injection, a TNFa inhibitor. This single-use autoinjector dosage form, prefilled with the same drug as the syringe dosage form, was launched in December 2022. The device is designed for ease of use, allowing users to inject the drug by pressing against the skin. The needle covering is locked after injection to prevent needle piercing accidents.

Application:-

Oncology segment is the fastest-growing segment in Injectable Drug Delivery market share

The oncology segment is the fastest-growing segment in the injectable drug delivery market share and is expected to hold the market share over the forecast period.

The oncology segment is driving growth in the global injectable drug delivery market, driven by the increasing prevalence of cancer worldwide. With approximately 20 million new cancer cases reported in 2023, the need for effective treatment options is urgent. Injectable drug delivery systems are advantageous in oncology due to their ability to administer complex biologics and immunotherapies for targeted cancer treatments.

Moreover, key market players are developing advanced injectable devices and formulations, including self-injectable devices and smart injectors, to enhance patient compliance and minimize dosing errors and also launching novel products help the segmet to grow during the forecast period.

For instance, Amneal Pharmaceuticals, Inc. announced the launch of PEMRYDI RTU, the first and the only ready-to-use presetation of pemetrexed for injection. Unlike other presentations, this product does not require the cool condition of reconstitution and dilution.

Geographical Analysis

North America is expected to hold a significant position in the Injectable Drug Delivery market share

North America holds a substantial position in the injectable drug delivery market and is expected to hold most of the market share due to increasing burden of chronic illnesses among adults, particularly diabetes, cancer, and autoimmune disorders. Besides, advanced healthcare infrastructure, hefty investment in research and development, and the organization of leading pharmaceutical firms all make the region a great potential market contributor. Moreover, when favorably wrapped with increasing self-injection, such as with insulin pens and further biologics, the reimbursement policies are sufficient to drive up this growing market.

For instance, in October 2023, Enable Injections has received FDA approval for the EMPAVELI Injector for subcutaneous delivery of EMPAVELI (pegcetacoplan), a medication for adults with paroxysmal nocturnal hemoglobinuria. The compact, wearable injector streamlines self-administration and minimizes disruption to patients' daily lives, making it a valuable tool for the treatment of PNH.

Europe is growing at the fastest pace in the Injectable Drug Delivery market

Europe holds the fastest pace in the injectable drug delivery market and is expected to hold most of the market share due to Europe has a good regulatory framework in most major markets, thus favoring uptake of these advanced injectable solutions. The focus on patient-driven drug delivery - such as prefilled syringes - is increasing across Europe, while treatment modalities are directed at home to avoid and limit hospital visits. The investment opportunity in this market further solidifies Europe's foothold in the expansion of the market. The current condition of an aging population with an upsurge incidence of chronic diseases across the region is what drives demand for injectable therapy.

For instance, in November 2024, Swiss medical technology company Ypsomed's has signed a new contract with Danish drugmaker Novo Nordisk, which includes the supply of injection pens for CagriSema, the company's next-generation experimental obesity drug. This deal provides insight into Novo's long-term planning for commercial production for its drug candidates, which are still being tested and hoped to be more powerful successors to its popular Wegovy injection.

Competitive Landscape

The major global players in the injectable drug delivery market include Becton Dickinson & Company, Baxter International, Inc, Gerresheimer AG, Pfizer Inc, Schott AG, Terumo Corporation, SHL Medical, Owen Mumford, Ypsomed, Union Medico and among others.

Key Developments

  • In January 2024, Credence MedSystems, a leading pharmaceutical drug delivery system innovator, has completed Factory Acceptance Testing (FAT) for the production of its Companion injection device platform on its new Clinical Assembly Line.
  • In June 2023, Stevanato Group, S.p.A., has introduced Vertiva, an On-Body Delivery System (OBDS) designed for switching between basal and bolus injections and suitable for various subcutaneous therapies. The unique design includes a single-use pod with a pre-filled 3mL ISO cartridge and a multi-use controller, offering sustainability and affordability benefits. The device can adapt to different delivery profiles and administer small-molecule drugs and biologics.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global injectable drug delivery market report delivers a detailed analysis with 70 key tables, more than 66 visually impactful figures, and 186 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Usage Patterns
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Prevalence of Chronic Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Complex Manufacturing
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Device Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 6.1.2. Market Attractiveness Index, By Device Type
  • 6.2. Autoinjectors*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Conventional injection devices
  • 6.4. Pen Injectors
  • 6.5. Wearable injectors
  • 6.6. Others

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Oncology*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Autoimmune Diseases
    • 7.2.4. Hormonal Disorders
    • 7.2.5. Orphan Disease
    • 7.2.6. Others

8. By Usage Pattern

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
    • 8.1.2. Market Attractiveness Index, By Usage Pattern
  • 8.2. Curative Care*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Immunization
  • 8.4. Other Usage Pattern

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage Pattern
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. Becton Dickinson & Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Baxter International, Inc
  • 12.3. Gerresheimer AG
  • 12.4. Pfizer Inc
  • 12.5. Schott AG
  • 12.6. Terumo Corporation
  • 12.7. SHL Medical
  • 12.8. Owen Mumford
  • 12.9. Ypsomed
  • 12.10. Union Medico
  • Similar data will be provided for each market player.

Emerging Market Players

  • 12.11. ApiJect Systems*
    • 12.11.1. Pipeline Products Description
    • 12.11.2. Product Key Performance Indicators (KPIs)
    • 12.11.3. Key Activities
    • 12.11.4. Market Entry Timelines
    • 12.11.5. Product Penetration Rate
    • 12.11.6. Sales Estimation and Projections
  • 12.12. Alteogen Inc
  • 12.13. Halozyme Therapeutics
  • 12.14. Carmot Therapeutics
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1 About Us and Services
  • 12.2 Contact Us